PharmaBoardroom

David Lescuyer – Managing Director, Skyepharma, France

David Lescuyer, managing director of Skyepharma, a specialized CDMO, reflects on the past three years of the company as it transitioned from a drug…

“Why We Need Public-Private Partnerships in Drug…

Pierre Meulien, Executive Director of the Innovative Medicines Initiative (IMI) in Europe, outlines the value of public-private partnerships in drug…

George Lee – Vice-President of Clinical Operations and…

George Lee, vice-president of clinical operations and country leader of PAREXEL in China, discusses the impact of the recent ownership and management…

South Korea Gives the Green Light to Imports of Medical Cannabis

This week the Korean Ministry of Food and Drug Safety announced that as of 12th March 2019 a revised narcotics bill will go into effect that will…

Top 10 Orphan Drugs in the USA

The Top 10 bestselling orphan drugs in the USA in 2017. Celgene's Revlimid (generic name lenolidamide) leads the way with sales of USD 5.4 billion,…

Zhou Mingdong – Founder & CEO, Zensun, China

One of the earliest innovative biotech companies in China, Zensun has developed what its founder Dr Zhou Mingdong calls a rare made-in-China…

Marc-Alexander Burmeister – President, B. Braun France

Dr Marc-Alexander Burmeister, president of B. Braun in France, shares the exciting changes to come for B. Braun globally and in France, and discusses…

Top 10 Global Orphan Drug Companies Ranking 2017

The top 10 companies in the world ranked by global orphan drug sales and market share in 2017. Swiss giants Novartis and Roche take the top two…

NEW Turkey Pharma Report Out Now!

Turkey – home to an 80 million-strong population, a substantial pharmaceuticals market and a universal healthcare system that is the envy of its…

Why Invest in Rare Diseases & Orphan Drugs?

In the run-up to Rare Disease Day 2019, David H. Crean, PhD, Managing Director for Objective Capital Partners, reviews the investment and deal…

A New Era in Access to Rare Disease Drugs in Canada

Durhane Wong-Rieger is the President & CEO of the Canadian Organization for Rare Disorders (CORD). In her first article for PharmaBoardroom,…

“Canada Needs to do Better in Supporting Innovative…

Brian Hilberdink, President of Novo Nordisk Canada, calls for the Canadian government to encourage and invest in innovative biopharmaceutical…

Tagged with